CDKN2B-AS1 and cancer: In addition, the high expression level of ANRIL was significantly associated with poor OS of patients with cancer, both equal to or greater than 5 years (HR: 2.07, 95% CI: 1.71–2.49, P < 0.00001) and less than 5 years (HR: 2.71, 95% CI: 1.53–4.82, P < 0.00001) (Table 4).